European commission (ec) approves livtencitytm▼ (maribavir) for the treatment of adults with post-transplant cytomegalovirus (cmv) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies

Osaka, japan & cambridge, mass.--( business wire )--takeda (tse:4502/nyse:tak) today announced that the european commission (ec) has granted marketing authorization for livtencitytm (maribavir) for the treatment of cytomegalovirus (cmv) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet, in adult patients who have undergone a haematopoietic stem cell transplant (hsct) or solid organ transplant (sot).4 livtencity is the first and only oral treatment that inhibits cmv-specific ul97 protein kinase and its natural substrates.1
TAK Ratings Summary
TAK Quant Ranking